Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|July 24, 2014
Early Treatment With Docetaxel for Metastatic Prostate Cancer
Author(s)Jyoti D. Patel, MD
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
Advertisement
Clinical Pearls
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
- Treatment with docetaxel early on improves survival for men who have early evidence of metastatic prostate cancer.
- Some patients have performance status that precludes treatment. As a result, they are never treated with the most active agents.
- This analysis will change practice: It will change who cares for patients early on and how they are treated.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
5